Search

Your search keyword '"van den Bent M"' showing total 633 results
Start Over Author "van den Bent M"
633 results on '"van den Bent M"'

201. Ongoing Clinical Trials

Author

Clarke, J. L., primary, Ennis, M. M., additional, Lamborn, K. R., additional, Prados, M. D., additional, Puduvalli, V. K., additional, Penas-Prado, M., additional, Gilbert, M. R., additional, Groves, M. D., additional, Hess, K. R., additional, Levin, V. A., additional, de Groot, J., additional, Colman, H., additional, Conrad, C. A., additional, Loghin, M. E., additional, Hunter, K., additional, Yung, W. K., additional, Chen, C., additional, Damek, D., additional, Liu, A., additional, Gaspar, L. E., additional, Waziri, A., additional, Lillehei, K., additional, Kavanagh, B., additional, Finlay, J. L., additional, Haley, K., additional, Dhall, G., additional, Gardner, S., additional, Allen, J., additional, Cornelius, A., additional, Olshefski, R., additional, Garvin, J., additional, Pradhan, K., additional, Etzl, M., additional, Goldman, S., additional, Atlas, M., additional, Thompson, S., additional, Hirt, A., additional, Hukin, J., additional, Comito, M., additional, Bertolone, S., additional, Torkildson, J., additional, Joyce, M., additional, Moertel, C., additional, Letterio, J., additional, Kennedy, G., additional, Walter, A., additional, Ji, L., additional, Sposto, R., additional, Dorris, K., additional, Wagner, L., additional, Hummel, T., additional, Drissi, R., additional, Miles, L., additional, Leach, J., additional, Chow, L., additional, Turner, R., additional, Gragert, M. N., additional, Pruitt, D., additional, Sutton, M., additional, Breneman, J., additional, Crone, K., additional, Fouladi, M., additional, Friday, B. B., additional, Buckner, J., additional, Anderson, S. K., additional, Giannini, C., additional, Kugler, J., additional, Mazurczac, M., additional, Flynn, P., additional, Gross, H., additional, Pajon, E., additional, Jaeckle, K., additional, Galanis, E., additional, Badruddoja, M. A., additional, Pazzi, M. A., additional, Stea, B., additional, Lefferts, P., additional, Contreras, N., additional, Bishop, M., additional, Seeger, J., additional, Carmody, R., additional, Rance, N., additional, Marsella, M., additional, Schroeder, K., additional, Sanan, A., additional, Swinnen, L. J., additional, Rankin, C., additional, Rushing, E. J., additional, Hutchins, L. F., additional, Damek, D. M., additional, Barger, G. R., additional, Norden, A. D., additional, Lesser, G., additional, Hammond, S. N., additional, Drappatz, J., additional, Fadul, C. E., additional, Batchelor, T. T., additional, Quant, E. C., additional, Beroukhim, R., additional, Ciampa, A., additional, Doherty, L., additional, LaFrankie, D., additional, Ruland, S., additional, Bochacki, C., additional, Phan, P., additional, Faroh, E., additional, McNamara, B., additional, David, K., additional, Rosenfeld, M. R., additional, Wen, P. Y., additional, Phuphanich, S., additional, Reardon, D., additional, Wong, E. T., additional, Plotkin, S. R., additional, Mintz, A., additional, Raizer, J. J., additional, Kaley, T. J., additional, Smith, K. H., additional, Chamberlain, M. C., additional, Graham, C., additional, Mrugala, M., additional, Johnston, S., additional, Kreisl, T. N., additional, Smith, P., additional, Iwamoto, F., additional, Sul, J., additional, Butman, J. A., additional, Fine, H. A., additional, Westphal, M., additional, Heese, O., additional, Warmuth-Metz, M., additional, Pietsch, T., additional, Schlegel, U., additional, Tonn, J.-C., additional, Schramm, J., additional, Schackert, G., additional, Melms, A., additional, Mehdorn, H. M., additional, Seifert, V., additional, Geletneky, K., additional, Reuter, D., additional, Bach, F., additional, Khasraw, M., additional, Abrey, L. E., additional, Lassman, A. B., additional, Hormigo, A., additional, Nolan, C., additional, Gavrilovic, I. T., additional, Mellinghoff, I. K., additional, Reiner, A. S., additional, DeAngelis, L., additional, Omuro, A. M., additional, Burzynski, S. R., additional, Weaver, R. A., additional, Janicki, T. J., additional, Burzynski, G. S., additional, Szymkowski, B., additional, Acelar, S. S., additional, Mechtler, L. L., additional, O'Connor, P. C., additional, Kroon, H.-A., additional, Vora, T., additional, Kurkure, P., additional, Arora, B., additional, Gupta, T., additional, Dhamankar, V., additional, Banavali, S., additional, Moiyadi, A., additional, Epari, S., additional, Merchant, N., additional, Jalali, R., additional, Moller, S., additional, Grunnet, K., additional, Hansen, S., additional, Schultz, H., additional, Holmberg, M., additional, Sorensen, M. M., additional, Poulsen, H. S., additional, Lassen, U., additional, Reardon, D. A., additional, Vredenburgh, J. J., additional, Desjardins, A., additional, Janney, D. E., additional, Peters, K., additional, Sampson, J., additional, Gururangan, S., additional, Friedman, H. S., additional, Jeyapalan, S., additional, Constantinou, M., additional, Evans, D., additional, Elinzano, H., additional, O'Connor, B., additional, Puthawala, M. Y., additional, Goldman, M., additional, Oyelese, A., additional, Cielo, D., additional, Dipetrillo, T., additional, Safran, H., additional, Anan, M., additional, Seyed Sadr, M., additional, Alshami, J., additional, Sabau, C., additional, Seyed Sadr, E., additional, Siu, V., additional, Guiot, M.-C., additional, Samani, A., additional, Del Maestro, R., additional, Bogdahn, U., additional, Stockhammer, G., additional, Mahapatra, A. K., additional, Venkataramana, N. K., additional, Oliushine, V. E., additional, Parfenov, V. E., additional, Poverennova, I. E., additional, Hau, P., additional, Jachimczak, P., additional, Heinrichs, H., additional, Schlingensiepen, K.-H., additional, Shibui, S., additional, Kayama, T., additional, Wakabayashi, T., additional, Nishikawa, R., additional, de Groot, M., additional, Aronica, E., additional, Vecht, C. J., additional, Toering, S. T., additional, Heimans, J. J., additional, Reijneveld, J. C., additional, Batchelor, T., additional, Mulholland, P., additional, Neyns, B., additional, Nabors, L. B., additional, Campone, M., additional, Wick, A., additional, Mason, W., additional, Mikkelsen, T., additional, Ashby, L. S., additional, DeGroot, J. F., additional, Gattamaneni, H. R., additional, Cher, L. M., additional, Rosenthal, M. A., additional, Payer, F., additional, Xu, J., additional, Liu, Q., additional, van den Bent, M., additional, Nabors, B., additional, Fink, K., additional, Chan, M., additional, Trusheim, J., additional, Raval, S., additional, Hicking, C., additional, Henslee-Downey, J., additional, Picard, M., additional, Schiff, D., additional, Karimi, S., additional, DeAngelis, L. M., additional, Nolan, C. P., additional, Omuro, A., additional, Gavrilovic, I., additional, Norden, A., additional, Purow, B. W., additional, Lieberman, F. S., additional, Hariharan, S., additional, Perez-Larraya, J. G., additional, Honnorat, J., additional, Chinot, O., additional, Catry-Thomas, I., additional, Taillandier, L., additional, Guillamo, J. S., additional, Campello, C., additional, Monjour, A., additional, Tanguy, M. L., additional, Delattre, J. Y., additional, Franz, D. N., additional, Krueger, D. A., additional, Care, M. M., additional, Holland-Bouley, K., additional, Agricola, K., additional, Tudor, C., additional, Mangeshkar, P., additional, Byars, A. W., additional, Sahmoud, T., additional, Alonso-Basanta, M., additional, Lustig, R. A., additional, Dorsey, J. F., additional, Lai, R. K., additional, Recht, L. D., additional, Paleologos, N., additional, Groves, M., additional, Meech, S., additional, Davis, T., additional, Pavlov, D., additional, Marshall, M. A., additional, Slot, M., additional, Peerdeman, S. M., additional, Beauchesne, P. D., additional, Faure, G., additional, Noel, G., additional, Schmitt, T., additional, Kerr, C., additional, Jadaud, E., additional, Martin, L., additional, Carnin, C., additional, Peters, K. B., additional, Herndon, J. E., additional, Kirkpatrick, J. P., additional, Nayak, L., additional, Panageas, K. S., additional, and Deangelis, L. M., additional

Published
2010
Full Text
View/download PDF

204. Low-grade astrocytoma, anaplastic oligodendroglioma or astrocytoma, and glioblastoma: The clinical trial portfolio of the EORTC Brain Tumor and Radiation Oncology Groups for newly diagnosed patients.

Author

Baumert, B., primary, Stupp, R., additional, Van Den Bent, M. J., additional, Erridge, S., additional, Brandes, A., additional, Pesce, G. A., additional, Weber, D. C., additional, Lacombe, D. A., additional, Gorlia, T., additional, and Wick, W., additional

Published
2010
Full Text
View/download PDF

205. Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Author

Pignatti, F., van den Bent, M J, Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Afra, D, Cornu, Philippe, Bolla, M., Vecht, C., Karim, A B M F, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council, De Witte, Olivier, Pignatti, F., van den Bent, M J, Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Afra, D, Cornu, Philippe, Bolla, M., Vecht, C., Karim, A B M F, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council, and De Witte, Olivier

Abstract

PURPOSE: To identify prognostic factors for survival in adult patients with cerebral low-grade glioma (LGG), to derive a prognostic scoring system, and to validate results using an independent data set. PATIENTS AND METHODS: European Organization for Research and Treatment of Cancer (EORTC) trial 22844 and EORTC trial 22845 are the largest phase III trials ever carried out in adult patients with LGG. The trials were designed to investigate the dosage and timing of postoperative radiotherapy in LGG. Cox analysis was performed on 322 patients from EORTC trial 22844 (construction set), and the results were validated on 288 patients from trial 22845 (validation set). Patients with pilocytic astrocytomas were excluded from this prognostic factor analysis. RESULTS: Multivariate analysis on the construction set showed that age > or = 40 years, astrocytoma histology subtype, largest diameter of the tumor > or = 6 cm, tumor crossing the midline, and presence of neurologic deficit before surgery were unfavorable prognostic factors for survival. The total number of unfavorable factors present can be used to determine the prognostic score. Presence of up to two of these factors identifies the low-risk group, whereas a higher score identifies high-risk patients. The validity of the multivariate model and of the scoring system was confirmed in the validation set. CONCLUSION: In adult patients with LGG, older age, astrocytoma histology, presence of neurologic deficits before surgery, largest tumor diameter, and tumor crossing the midline were important prognostic factors for survival. These factors can be used to identify low-risk and high-risk patients., Journal Article, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2002

206. EORTC Brain Tumor Group: achievements and perspectives.

Author

Vecht, C., van den Bent, M J, Lacombe, Denis, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council, De Witte, Olivier, Vecht, C., van den Bent, M J, Lacombe, Denis, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council, and De Witte, Olivier

Abstract

The EORTC Brain Tumor Group has a long standing history of achievements. The activities of the Brain Tumor Group have recently been re-structured in order to face the challenge of large intergroup/intercontinental trials and be a reference address for early drug development needed for gliomas. Constant adaptation to higher quality assurance criteria and implementation of translational research studies are now priorities for the Brain Tumor Group. Due to such activities, the EORTC Brain Group has become a major player in clinical research. The number of centres and patients joining its trials have greatly increased over the past 2 years. Achievements and strategies are detailed in this article., Journal Article, info:eu-repo/semantics/published

Published
2002

207. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

Author

Dubbink, H. J., primary, Taal, W., additional, van Marion, R., additional, Kros, J. M., additional, van Heuvel, I., additional, Bromberg, J. E., additional, Zonnenberg, B. A., additional, Zonnenberg, C.B.L., additional, Postma, T. J., additional, Gijtenbeek, J. M.M., additional, Boogerd, W., additional, Groenendijk, F. H., additional, Smitt, P. A.E. Sillevis, additional, Dinjens, W. N.M., additional, and van den Bent, M. J., additional

Published
2009
Full Text
View/download PDF

208. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Author

Reardon, D A, primary, Dresemann, G, additional, Taillibert, S, additional, Campone, M, additional, van den Bent, M, additional, Clement, P, additional, Blomquist, E, additional, Gordower, L, additional, Schultz, H, additional, Raizer, J, additional, Hau, P, additional, Easaw, J, additional, Gil, M, additional, Tonn, J, additional, Gijtenbeek, A, additional, Schlegel, U, additional, Bergstrom, P, additional, Green, S, additional, Weir, A, additional, and Nikolova, Z, additional

Published
2009
Full Text
View/download PDF

210. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

Author

Jaeckle, K. A., Phuphanich, S., Van den Bent, M. J., Aiken, R., Batchelor, T., Campbell, T., Fulton, D., Gilbert, M., Heros, D., Rogers, L., O'Day, S. J., Akerley, W., Allen, J., Baidas, S., Gertler, S. Z., Greenberg, H. S., LaFollette, S., Lesser, G., Mason, W., Recht, L., Wong, E., Chamberlain, M. C., Cohn, A., Glantz, M. J., Gutheil, J. C., Maria, B., Moots, P., New, P., Russell, C., Shapiro, W., Swinnen, L., Howell, S. B., Jaeckle, K. A., Phuphanich, S., Van den Bent, M. J., Aiken, R., Batchelor, T., Campbell, T., Fulton, D., Gilbert, M., Heros, D., Rogers, L., O'Day, S. J., Akerley, W., Allen, J., Baidas, S., Gertler, S. Z., Greenberg, H. S., LaFollette, S., Lesser, G., Mason, W., Recht, L., Wong, E., Chamberlain, M. C., Cohn, A., Glantz, M. J., Gutheil, J. C., Maria, B., Moots, P., New, P., Russell, C., Shapiro, W., Swinnen, L., and Howell, S. B.

Abstract

Depocyte is a slow-release formulation of cytarabine designed for intrathecal administration. The goal of this multi-centre cohort study was to determine the safety and efficacy of DepoCyte for the intrathecal treatment of neoplastic meningitis due to breast cancer. DepoCyte 50 mg was injected once every 2 weeks for one month of induction therapy; responding patients were treated with an additional 3 months of consolidation therapy. All patients had metastatic breast cancer and a positive CSF cytology or neurologic findings characteristic of neoplastic meningitis. The median number of DepoCyte doses was 3, and 85% of patients completed the planned 1 month induction. Median follow up is currently 19 months. The primary endpoint was response, defined as conversion of the CSF cytology from positive to negative at all sites known to be positive, and the absence of neurologic progression at the time the cytologic conversion was documented. The response rate among the 43 evaluable patients was 28% (CI 95%: 14-41%); the intent-to-treat response rate was 21% (CI 95%: 12-34%). Median time to neurologic progression was 49 days (range 1-515 +); median survival was 88 days (range 1-515 +), and 1 year survival is projected to be 19%. The major adverse events were headache and arachnoiditis. When drug-related, these were largely of low grade, transient and reversible. Headache occurred on 11% of cycles; 90% were grade 1 or 2. Arachnoiditis occurred on 19% of cycles; 88% were grade 1 or 2. DepoCyte demonstrated activity in neoplastic meningitis due to breast cancer that is comparable to results reported with conventional intrathecal agents. However, this activity was achieved with one fourth as many intrathecal injections as typically required in conventional therapy. The every 2 week dose schedule is a major advantage for both patients and physicians.

Published
2001

212. The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG

Author

Taphoorn, M. J., primary, Claassens, L., additional, Aaronson, N. K., additional, Coens, C., additional, Mauer, M., additional, Osoba, D., additional, Stupp, R., additional, Mirimanoff, R., additional, Van den Bent, M. J., additional, and Bottomley, A., additional

Published
2008
Full Text
View/download PDF

213. Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU)

Author

van den Bent, M. J., primary, Wick, W., additional, Liepa, A. M., additional, Puduvalli, V. K., additional, Carpentier, A. F., additional, Cher, L., additional, Mason, W. P., additional, Taphoorn, M. J., additional, Hong, S., additional, and Fine, H. A., additional

Published
2008
Full Text
View/download PDF

214. Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone

Author

Mirimanoff, R., primary, Mason, W., additional, Van den Bent, M., additional, Kortmann, R., additional, Taphoorn, M., additional, Brandes, A., additional, Villa, S., additional, Cairncrosss, G., additional, Gorlia, T., additional, and Stupp, R., additional

Published
2007
Full Text
View/download PDF

215. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

Author

Mauer, M, primary, Stupp, R, additional, Taphoorn, M J B, additional, Coens, C, additional, Osoba, D, additional, Marosi, C, additional, Wong, R, additional, de Witte, O, additional, Cairncross, J G, additional, Efficace, F, additional, Mirimanoff, R O, additional, Forsyth, P, additional, van den Bent, M J, additional, Weller, M, additional, and Bottomley, A, additional

Published
2007
Full Text
View/download PDF

217. EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial

Author

Brandes, A. A., primary, Stupp, R., additional, Hau, P., additional, Sleijfer, S., additional, Lacombe, D., additional, Gorlia, T., additional, Yun, H., additional, Tosoni, A., additional, Mirimanoff, R., additional, and van den Bent, M. J., additional

Published
2007
Full Text
View/download PDF

221. Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

Author

van den Bent, M., primary, Brandes, A., additional, Frenay, M., additional, Fumoleau, P., additional, Stupp, R., additional, Dittrich, C., additional, Coudert, B., additional, Clement, P., additional, Lacombe, D., additional, and Raymond, E., additional

Published
2005
Full Text
View/download PDF

226. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

Author

Triebels, V. H.J.M., primary, Taphoorn, M. J.B., additional, Brandes, A. A., additional, Menten, J., additional, Frenay, M., additional, Tosoni, A., additional, Kros, J. M., additional, Stege, E. B.-t., additional, Enting, R. H., additional, Allgeier, A., additional, van Heuvel, I., additional, and van den Bent, M. J., additional

Published
2004
Full Text
View/download PDF

229. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group

Author

Stupp, R., primary, Mason, W. P., additional, Van Den Bent, M. J., additional, Weller, M., additional, Fisher, B., additional, Taphoorn, M., additional, Brandes, A. A., additional, Cairncross, G., additional, Lacombe, D., additional, and Mirimanoff, R. O., additional

Published
2004
Full Text
View/download PDF

232. Hersentumoren.

Author

Anten, M. H. M. E., Dirven, C. M. F., and van den Bent, M. J.

Abstract

Copyright of Het Oncologie Formularium is the property of Springer eBooks and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2010
Full Text
View/download PDF

245. Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material.

Author

Gravendeel, L A M, de Rooi, J J, Eilers, P H C, van den Bent, M J, Sillevis Smitt, P A E, and French, P J

Subjects
GENE expression, GLIOMAS, POLYOXYMETHYLENE, CLINICAL trials, CANCER treatment, DIAGNOSIS, BRAIN tumors, PATIENTS
Abstract

Background:We have recently demonstrated that expression profiling is a more accurate and objective method to classify gliomas than histology. Similar to most expression profiling studies, our experiments were performed using fresh frozen (FF) glioma samples whereas most archival samples are fixed in formalin and embedded in paraffin (FFPE). Identification of the same, expression-based intrinsic subtypes in FFPE-stored samples would enable validation of the prognostic value of these subtypes on these archival samples. In this study, we have therefore determined whether the intrinsic subtypes identified using FF material can be reproduced in FFPE-stored samples.Methods:We have performed expression profiling on 55 paired FF-FFPE glioma samples using HU133 plus 2.0 arrays (FF) and Exon 1.0 ST arrays (FFPE). The median time in paraffin of the FFPE samples was 14.1 years (range 6.6-26.4 years).Results:In general, the correlation between FF and FFPE expression in a single sample was poor. We then selected the most variable probe sets per gene (n=17 583), and of these, the 5000 most variable probe sets on FFPE expression profiles. This unsupervised selection resulted in a better concordance (R2=0.54) between expression of FF and FFPE samples. Importantly, this probe set selection resulted in a correct assignment of 87% of FFPE samples into one of seven intrinsic subtypes identified using FF samples. Assignment to the same molecular cluster as the paired FF tissue was not correlated to time in paraffin.Conclusion:We are the first to examine a large cohort of paired FF and FFPE samples. We show that expression data from FFPE material can be used to assign samples to intrinsic molecular subtypes identified using FF material. This assignment allows the use of archival material, including material derived from large-randomised clinical trials, to determine the predictive and/or prognostic value of 'intrinsic glioma subtypes' on Exon arrays. This would enable clinicians to provide patients with an objective and accurate diagnosis and prognosis, and a personalised treatment strategy. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

247. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Author

van den Bent, M. J., Afra, D., de Witte, O., Hassel, M. Ben, Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Karim, A. B. M. F., and Mirimanoff, R.

Subjects
*GLIOMA treatment, *RADIOTHERAPY, *PROGNOSIS, *MEDICAL care research, *RESEARCH methodology
Abstract

Summary Background Postoperative policies of "wait-and-see" and radiotherapy for low-grade glioma are poorly defined. A trial in the mid 1980s established the radiation dose. In 1986 the EORTC Radiotherapy and Brain Tumor Groups initiated a prospective trial to compare early radiotherapy with delayed radiotherapy. An interim analysis has been reported. We now present the long-term results. Methods After surgery, patients from 24 centres across Europe were randomly assigned to either early radiotherapy of 54 Gy in fractions of 1·8 Gy or deferred radiotherapy until the time of progression (control group). Patients with low-grade astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and incompletely resected pilocytic astrocytoma, with a WHO performance status 0-2 were eligible. Analysis was by intention to treat, and primary endpoints were overall and progression-free survival. Findings 157 patients were assigned early radiotherapy, and 157 control. Median progression-free survival was 5·3 years in the early radiotherapy group and 3·4 years in the control group (hazard ratio 0·59, 95% CI 0·45-0·77; p<0·0001). However, overall survival was similar between groups: median survival in the radiotherapy group was 7·4 years compared with 7·2 years in the control group (hazard ratio 0·97, 95% CI 0·71-1·34; p=0·872). In the control group, 65% of patients received radiotherapy at progression. At 1 year, seizures were better controlled in the early radiotherapy group. Interpretation Early radiotherapy after surgery lengthens the period without progression but does not affect overall survival. Because quality of life was not studied, it is not known whether time to progression reflects clinical deterioration. Radiotherapy could be deferred for patients with low-grade glioma who are in a good condition, provided they are carefully monitored. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results